GPC Biotech: Preclinical data shows satraplatin with docetaxel superior in treating lung cancer

By E. Janene Geiss

Philadelphia, April 3 - GPC Biotech AG said Monday that new preclinical data on its lead drug candidate satraplatin showed that when combined with docetaxel in treating mice with non-small cell lung carcinoma results were superior to the best result obtained with either agent administered individually with no apparent increase in toxicity.

Within the range of doses and schedules tested, a combination of the two compounds administered sequentially results in therapeutically synergistic effects, according to a company news release.

The preclinical results build on previous data evaluating satraplatin in combination with Taxotere in cells and may be useful in developing appropriate dosing schedules for clinical testing of a combination therapy of satraplatin and Taxotere, officials said.

The data were presented at the annual meeting of the American Association for Cancer Research in Washington, D.C.

The company said it has two phase 1 trials evaluating satraplatin in combination with Taxotere in advanced solid tumors and a phase 2 study evaluating satraplatin in metastatic breast cancer.

"We expect to further explore satraplatin in this treatment setting in combination with other therapies, such as Herceptin," Marcel Rozencweig, senior vice president of drug development, said in the release.

Satraplatin, an investigational drug, is a member of the platinum family of compounds. Over the past two decades, platinum-based drugs have become a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. Unlike the platinum drugs currently on the market, all of which require intravenous administration, satraplatin is an orally bioavailable compound and is given as capsules that patients can take at home.

GPC Biotech is a Munich, Germany, biopharmaceutical company developing new anticancer drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.